The clinical effect of mifepristone combined with Guizhifuling capsule in the treatment of uterine fibroids
10.3760/cma.j.issn.1008-6706.2015.22.021
- VernacularTitle:米非司酮联合桂枝茯苓胶囊治疗子宫肌瘤的临床效果观察
- Author:
Yachun HU
- Publication Type:Journal Article
- Keywords:
Mifepristone;
Guizhifuling capsule;
Uterine leiomyoma;
Clinical effect;
Prognosis
- From:
Chinese Journal of Primary Medicine and Pharmacy
2015;(22):3422-3424
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical effect of mifepristone combined with Guizhifuling tuckahoe capsule for the treatment of uterus myoma,and to observe and analyze the prognosis and provide the basis for clinical treatment.Methods 150 uterus myoma patients were selected and randomly divided into the observation group and the control group according to the treatment number,75 cases in each group.The control group was treated with mife-pristone,the observation group was treated with mifepristone combined with Guizhifuling capsule.Treated for 12 weeks and the clinical therapeutic effect and the adverse reaction were evaluated.The follicle stimulating hormone (FSH), estradiol (E2 )levels before and after treatment were detected.Results The cure rate of the observation group was 85.33% (64 /75),which was higher than that of the control group 77.33% (58 /75),the difference was statistically significant (χ2 =10.35,P <0.05).The incidence rate of adverse reaction between the two groups had no statistically significant difference (P >0.05).The menstruation,menstrual volume and tumor size of the observation group after treatment were (47.50 ±3.85)mL,(4.15 ±1.22)mm and (11.26 ±0.98)cm3 respectively,which were lower than the control group after treatment,two groups were lower than that before treatment,the differences were statistically significant (t =9.88,10.13,10.22,all P <0.05).Serum FSH and LH levels of the observation group after treatment were (32.06 ±2.75)U /L and (31.16 ±2.13)U /L,which were lower than the control group after treatment,two groups were lower than that before treatment,the differences were statistically significant (t =9.67,10.04,all P <0.05).Serum E2 of the observation group was (51.40 ±3.34)pmol/L,which was higher than that of the control group (39.32 ±3.26)pmol/L,the two groups were higher than before treatment,the difference was statistically signif-icant (t =9.81,P <0.05).Conclusion Application of mifepristone combined with Guizhifuling capsule for the treatment of uterus myoma patients with child -bearing period has better clinical efficacy and can significantly improve patients menstrual status and sex hormone secretion.The adverse reactions has no significant differences.It is worth of clinical application.
